Connect with us


Avenir Capital 1Q20 Commentary

Avenir Capital 1Q20 Commentary



Avenir Capital commentary for the first quarter ended March 31, 2020, discussing a new addition to their portfolio, Wuliangye Yibin.

Dear Partner:

The Avenir Global Fund (the “Fund”) declined 25.2% for the March 2020 quarter bringing the past 1-year return to -18.1% (net)1. The MSCI ACWI index (AUD) returned -9.7% for the quarter and 3% for the past year.

Get The Full Seth Klarman Series in PDF

Get the entire 10-part series on Seth Klarman in PDF. Save it to your desktop, read it on your tablet, or email to your colleagues.

Q1 2020 hedge fund letters, conferences and more

The last two months have been unlike anything most investors have ever seen. In mid-February, markets were at all-time highs and it was almost impossible for investors to imagine anything that could cloud the horizon. By the middle of March, we were all conducting Zoom calls from our living rooms, as we hid indoors, and watching the same market fall into bear market territory faster than ever before, reaching a trough 35% below the peak2. Value underperformed significantly as investors sought defensive havens, not cyclically exposed or leveraged names. Energy, in particular, was hit hard, with the oil price down 47% in March alone.

Outperformers during the month were Clear Media, Cigna, Wuliangye Yibin and new portfolio entry, Visa. We have written about Clear Media in the past but as we had hoped, the company received a tender offer from a consortium at a 50% premium. We have now exited the stock. Cigna benefitted in part from Biden's presumptive nomination as the Democratic candidate in the US presidential election. Wuliangye Yibin, our Chinese liquor maker outperformed global markets as China began its slow return to normal activity. We added Visa to the portfolio in the month, opportunistically building a position in what we believe is one of the world's great franchises when it fell 40% from recent highs.

The largest detractors to performance in March were ECN Capital, Nexstar Media, Synchrony Financial, Spirit Airlines and General Motors. In the case of ECN, Synchrony and GM, prices fell predominantly due to market concerns that a spike in unemployment would have an impact on consumer spending. Synchrony is a provider of credit to consumers and ECN is essentially a distribution channel for banks and non-bank financials to provide credit to consumers albeit not taking on material credit risk itself. In the case of GM, car purchases are large commitments predominantly made with credit and previous recessions have typically resulted in falling car sales. In the case of Nexstar, it completed an acquisition in late 2019 which has left it relatively levered and as a result indirectly impacted by the temporary seizing up of corporate debt markets, even though in Nexstar's case, the bulk of their debt is not due until 2024 and beyond.

Barron’s magazine recently featured Avenir’s analysis of the company, Live Nation. You can find the Barron’s article here.

Market Commentary

The Covid-19 crisis is a dynamic and rapidly evolving situation. Governments and communities around the world have taken increasingly tough measures in order to control the health emergency, and the likely outcome of these efforts is resulting in the broad-based shutdown of economic activity for a period of unknown duration but, at least, several months.

The full outcome of the economic downturn will be a function of how long the health crisis lasts, until people are able to return to work, and subsequently, how long it takes for demand to return to normal levels. No-one knows for sure if we will see a V-shaped recovery, a U-shaped recovery or, something even worse, such as a long and deep recession or even depression. At this point, following the sharp market rebound from the lows on 23rd March, the market seems to be anticipating a short, sharp Vshaped recovery, although the economic evidence for this is less than clear.

The unprecedented threat to economic activity has seen equity market around the world suffer from some of the steepest falls ever witnessed. Since global markets peaked on February 19th, they have fallen by ~30%, wiping roughly U$23 trillion from the value of global equity markets. The S&P 500 fell 34% to its lows3, in the process, gaining the dubious distinction of being the fastest ever fall of more than 20%. Since the market low, it has bounced back strongly to be only 14% below its all-time highs4. During March, the Dow Jones recorded two of the top five worst one-day performances of all time5. Common volatility measures like the VIX have hit all-time highs, and, in fact, outside of the global financial crises, 5 of the all-time high closes for the VIX occurred in the month of March 2020, so we are witnessing one of the most volatile periods in financial market history6.

The good news is that governments around the world are taking extraordinary measures in order to protect the global economy. The US has promised fiscal stimulus of US$2.4 trillion7 (~11% of GDP)8 to support both small and large businesses along with individuals and may well go higher. European countries are also promising to do “whatever it takes” announcing massive fiscal stimulus programs and support for businesses and individuals affected by the crises. The UK has pledged £350 billion9 of stimulus. In Australia, the figure moves by the day but is equally impressive with the federal government announcing fiscal stimulus of over A$320 billion to date, or 16% of GDP10. These unprecedented measures should help to limit the economic fall out of the crises.

Portfolio Activity

So, what are we at Avenir doing during this crisis? We have taken steps to protect our investors’ capital including reducing our exposure to some of those sectors most directly impacted by the crises including travel related and other more cyclical businesses, and increasing our cash weighting to approximately 15%. We have been working through each company in our portfolio to assess both the near-term impact on our companies and to determine whether they have the liquidity and balance sheet strength to weather the storm and to confirm that our long-term investment cases are intact.

Importantly, we are working to position the portfolio to both protect capital and generate attractive returns for our investors over the next 3-5 years. This can mean proactively trimming more fully valued positions in our portfolio, or those which have been less affected by the share price volatility and adding to those which have been most affected by the market downturn and in which the price-tovalue gap has increased significantly.

The unprecedented volatility has also reduced the price of some high-quality businesses that we don’t currently own and that have been on our Watchlist but have not previously been at valuation levels that have been attractive to us. We will continue to look for opportunities to selectively add high-quality but heavily-discounted names to the portfolio. It is at times of economic and market stress like this that some of the best long-term investment opportunities can be found.

New Addition: Wuliangye Yibin

As some specific examples, we have added Wuliangye Yibin, a Chinese baijiu or alcoholic beverage company, to the portfolio. Wuliangye Yibin has a very attractive competitive position and has delivered earnings growth of over 20% per annum over the past five years. Wuliangye Yibin has many of the characteristics we look for in investments: compelling end market growth in a defensive category, strong market share, high returns on capital and the ability to deploy additional capital at high rates of return, pricing power and a competitive moat created by long standing-consumer brands.

We have also recently added Visa to the portfolio. Visa is a duopoly business that generates tremendous returns on capital and has ample scope to continue to invest capital at high returns. Visa has been a wonderful business for a long time and the near 40% fall in price between 19th February and 23rd March this year gave us the opportunity to add it to the portfolio.

Our largest position in the portfolio currently is Charter, the U.S. broadband business. Charter’s business is very resilient in the current environment where people are working and being schooled from home and the need for data connectivity continues to grow in the modern world. We believe the near term for Charter is well protected and the long term offers tremendous value creation opportunity.

We also have material positions in major health businesses like Cigna and HCA Healthcare which, while potentially affected in the near term, being at the forefront of the health crisis, are world class businesses and we believe they have enormous long-term value.


As always, all members of the Avenir investment team are invested in the Fund alongside our investors, and while the current uncertainty and volatility can be very unsettling, we believe that the portfolio is currently trading at deeply discounted levels with the embedded margin of safety and prospective five-year returns as high as they have ever been.

The coronavirus has shut down the economy to an extent not witnessed before and economically sensitive and smaller capitalisation stocks have been severely punished. This covers a very wide range of the economy capturing banks and other financial institutions, energy, travel related companies, hotels, entertainment and restaurant businesses, home builders, auto companies, etc. The fall out has also affected companies previously regarded as infrastructure assets, including airports and toll roads, which have seen revenues approaching zero. Smaller companies have been affected much more than larger companies. The Russell 2000 was down 31% to the end March compared to the S&P 500 which was down 19%11.

Many of the companies most affected by this pandemic are those that were already trading at heavily discounted valuations. At the same time, the market has bid up those companies that will benefit, at least temporarily, from the current crisis, including supermarkets, Netflix, Amazon, etc. Many of these companies had already benefited from 5 years of market conditions that favoured high growth companies with potential high future earnings in a world of low interest rates.

Consequently, the valuation dispersion between the most expensive and the cheapest, which was already high, has now grown even more pronounced. Many of the market leading firms, even after recent falls, are still trading at valuations near, or in excess of, their long-term averages. McDonalds, for example, has fallen 20% from its highs but still trades at a trailing EBIT multiple12 of 20x compared to its average over the past 5-years of 18.3x. In other words, the recent price decline has not made it particularly cheap compared to its own history. We don’t highlight McDonalds, which is a very highquality and resilient company, for any reason other than it is well known.

Apple is another example, which has fallen 17% from its highs (after having fallen as much as 32%, to a recent low of $224, before rebounding) but still trades at 18x EBIT, a 38% premium to its 5-year average of 13x. Much of this multiple expansion occurred during 2019, and we commented in our December 2019 letter that it was difficult to see exactly what had changed during 2019 to justify the market rewarding Apple with an extra $560 billion of market capitalisation and a multiple that is 4-standard deviations greater than its average for the past decade.

There are many similar examples of companies that have fallen by substantial amounts to still sit well above their own long-term trading multiples. This is, of course, due to the elevated level at which markets (the U.S. in particular) were trading at the end of 2019. Prior to the recent abrupt market crash, the Shiller PE was in excess of 30x, a figure only breached twice before in market history, in 1929 and in the 1990-2000 peak13. Even today14, the Shiller PE sits at 27x compared to its long-term average of 17x. Despite the pandemic we are facing and the near total economic shut down, ongoing geopolitical tension, oil price crashes, the potential for inflation following $7+ trillion of money printing by global central banks, potential decoupling of supply chains, etc, the S&P 500 trades nearly 60% above its long-term average trading multiple.

At the other end of the spectrum is Univar Solutions, one of our portfolio companies. Univar is a chemical distribution business and so is impacted by the level of underlying economic activity. Its share price has been significantly impacted by the coronavirus induced economic slowdown. From its quarter opening price of $24, Univar’s share price declined 74% to its low of $6.40, before rebounding 68% to its quarter-end price of $10.72. At that price, Univar traded at 12x trailing EBIT, a 37% discount to its 5-year average of 19x trailing EBIT. While Univar is, no doubt, somewhat economically sensitive, it is exposed to a range of industries and is largely a consumbles business so revenue is recurring and not subject to dramatic swings like a capital equipment provider.

During the 2008/2009 financial crises, Univar’s rolling twelve month EBITDA declined by only 12.4% from the peak in 4Q2008 to the trough in 4Q2009. Twelve months later (4Q2010) EBITDA had rebounded to its previous high. Univar has market leadership positions in a relatively stable and high return market, limited capital intensity and high free cash flow generation. The company has many suppliers, and even more customers, reducing the potential for unexpected shocks. It is hard to see the chemical distribution industry being disrupted in any meaningful way. Univar also has a high working capital position so, any revenue decline leads to high cash generation as the working capital unwinds, adding to the economic resilience of the business.

In fact, the chemical distribution industry has been a favourite hunting ground of the private equity industry due to its underyling resilience and lack of secular or disruptive threats. Univar, itself, was only returned to the public market in 2015 after a lengthy period in private equity ownership. As of 2013, 5 of the top 7 global chemical distribution businesses were owned by private equity firms highlighting the suitability of these firms for PE ownership. It is quite possible (likely?) that private equity make another play for Univar at some point and that possibility alone should help to provide some kind of a floor under the share price. If Univar were to simply return to its 5-year average multiple, on our view of normalised earnings, we think it possible for the share price to climb to $30 per share or 150% higher than the current price. Univar currently trades at close to a 20% free cash flow yield based on normalised earnings. While the company does carry some debt, it has no major debt maturities until 2024 and its average interest rate is 4.25%, so, we believe it is well placed to weather thes storm and deliver very attractive returns from here.

Regardless of the short-term impact of Covid-19, we believe that the prospects for broad based market returns over the next 5-10 years remain subdued. Over the near term, returns are likely to be determined by investor psychology and behaviour as much as they are by fundamental outcomes. Over the long-term, the fundamental performance of businesses and the price investors pay for those business will win out. Current market stress and volatility, and the wholesale selling of anything with any kind of economic sensitivity, is setting up some extraordinary long-term investment opportunities.

O’Shaughnessy Asset Management (OSAM), a U.S. based quantitative investment firm, calculate that the spread between the earnings yield15 on small cap value and the yield on the U.S. government 10-year bond, which is normally 3-6%, is currently 20%16. Less than 1% of all data observations show a higher earnings yield spread, so the spread is at truly historic proportions. OSAM calculate that in the 10-year period following past observations of such a high spread, small cap value returned 27.9% per year. While the current market dynamics make for a chaotic and, indeed, frustrating period, we believe that it increases the potential for our value-based strategy to outperform the market over the next 5-10 years.

Is Inflation a Thing?

People have long been talking about the central bank ‘experiment’ that has been taking place around the world with the enormous expansion of central bank balance sheets and generational low interest rates. The central bank balance sheet expansion that has occurred post the global financial crisis, however, has been a drop in the bucket compared to the money printing that is being undertaken now as a response to the coronavirus crisis and the unprecedented shutdown of the global economy. Dare we raise the prospect that inflation may rear its head at some point following the extraordinary money printing we are witnessing?

Inflation has also, arguably, been low due to the globalisation that the world has benefited from for the last 30-years. We are now likely to see a reduction in those benefits as companies and countries increasingly ‘decouple’ to avoid being strategically disadvantaged by having supply chains deeply embedded in another country that may turn against them for political reasons. We don’t know the answer, but is it out of the bounds of possibility that inflation and higher interest rates may follow from these factors at some point? If that is the case, then long dated options, like unprofitable but fastgrowing companies, may not be valued in the future the way they are today. These, and many other companies, despite recent falls, still appear priced for perfection, even though we are in the middle of one of the greatest economic shocks we have ever witnessed. Now is a time for operating with a scalpel not a sledgehammer, and we prefer the make-up of our concentrated portfolio to the broader market that appears to be doing its best to ignore the current economic conditions.

Portfolio Positioning

The type of business we favour has not changed and we would still rather buy high quality but appropriately priced businesses than businesses priced for perfection in the current uncertain environment. We are value-oriented investors but we don’t simply buy ‘cheap’ companies. Robust, well-capitalised businesses that can grow underlying value are still, and always will be, our hunting ground. Periods of volatility are also a sweet spot of ours as it allows us to continually improve our margin of safety by reallocating capital from companies with a higher price-to-value ratio to those with a lower price-to-value ratio. By doing so, we aim to substantially reduce risk and increase the prospective returns for the portfolio.

We consider that the Avenir portfolio currently trades at 50%17 of our view of underlying value positioning the portfolio for robust returns over the next 3-5 years. We have not seen such attractive portfolio positioning for many years and investors may consider this as an opportune time to allocate capital to Avenir Capital.

It is important for investors to maintain a long-term view and not have long-term investment goals derailed by short-term events. This is a complex, fast moving and unprecedented situation and we will continue to take thoughtful and measured action to best position the portfolio for the current conditions and to deliver attractive investment returns over the longer-term.


Our private equity heritage encourages us to view every investment we make as if we are buying the whole company. This helps to keep our focus on the quality of the underlying business, its long-term prospects and the price we are being asked to pay, rather than trying to speculate as to what the market or individual company prices may do over the short-term.

We believe that our fundamental research-driven and concentrated investment approach will continue to generate attractive investment outcomes for our investors, and the team at Avenir remain
enthusiastic and focused in our search for the next great investment.

“There is nothing more deceptive than an obvious fact.” - Arthur Conan Doyle

Best Regards,

Adrian Warner

Managing Director

The post Avenir Capital 1Q20 Commentary appeared first on ValueWalk.

Read More

Continue Reading


Glimpse Of Sanity: Dartmouth Returns Standardized Testing For Admission After Failed Experiment

Glimpse Of Sanity: Dartmouth Returns Standardized Testing For Admission After Failed Experiment

In response to the virus pandemic and nationwide…



Glimpse Of Sanity: Dartmouth Returns Standardized Testing For Admission After Failed Experiment

In response to the virus pandemic and nationwide Black Lives Matter riots in the summer of 2020, some elite colleges and universities shredded testing requirements for admission. Several years later, the test-optional admission has yet to produce the promising results for racial and class-based equity that many woke academic institutions wished.

The failure of test-optional admission policies has forced Dartmouth College to reinstate standardized test scores for admission starting next year. This should never have been eliminated, as merit will always prevail. 

"Nearly four years later, having studied the role of testing in our admissions process as well as its value as a predictor of student success at Dartmouth, we are removing the extended pause and reactivating the standardized testing requirement for undergraduate admission, effective with the Class of 2029," Dartmouth wrote in a press release Monday morning. 

"For Dartmouth, the evidence supporting our reactivation of a required testing policy is clear. Our bottom line is simple: we believe a standardized testing requirement will improve—not detract from—our ability to bring the most promising and diverse students to our campus," the elite college said. 

Who would've thought eliminating standardized tests for admission because a fringe minority said they were instruments of racism and a biased system was ever a good idea? 

Also, it doesn't take a rocket scientist to figure this out. More from Dartmouth, who commissioned the research: 

They also found that test scores represent an especially valuable tool to identify high-achieving applicants from low and middle-income backgrounds; who are first-generation college-bound; as well as students from urban and rural backgrounds.

All the colleges and universities that quickly adopted test-optional admissions in 2020 experienced a surge in applications. Perhaps the push for test-optional was under the guise of woke equality but was nothing more than protecting the bottom line for these institutions. 

A glimpse of sanity returns to woke schools: Admit qualified kids. Next up is corporate America and all tiers of the US government. 

Tyler Durden Mon, 02/05/2024 - 17:20

Read More

Continue Reading


Four burning questions about the future of the $16.5B Novo-Catalent deal

To build or to buy? That’s a classic question for pharma boardrooms, and Novo Nordisk is going with both.
Beyond spending billions of dollars to expand…



To build or to buy? That’s a classic question for pharma boardrooms, and Novo Nordisk is going with both.

Beyond spending billions of dollars to expand its own production capacity for its weight loss drugs, the Danish drugmaker said Monday it will pay $11 billion to acquire three manufacturing plants from Catalent. It’s part of a broader $16.5 billion deal with Novo Holdings, the investment arm of the pharma’s parent group, which agreed to acquire the contract manufacturer and take it private.

It’s a big deal for all parties, with potential ripple effects across the biotech ecosystem. Here’s a look at some of the most pressing questions to watch after Monday’s announcement.

Why did Novo do this?

Novo Holdings isn’t the most obvious buyer for Catalent, particularly after last year’s on-and-off M&A interest from the serial acquirer Danaher. But the deal could benefit both Novo Holdings and Novo Nordisk.

Novo Nordisk’s biggest challenge has been simply making enough of the weight loss drug Wegovy and diabetes therapy Ozempic. On last week’s earnings call, Novo Nordisk CEO Lars Fruergaard Jørgensen said the company isn’t constrained by capital in its efforts to boost manufacturing. Rather, the main challenge is the limited amount of capabilities out there, he said.

“Most pharmaceutical companies in the world would be shopping among the same manufacturers,” he said. “There’s not an unlimited amount of machinery and people to build it.”

While Novo was already one of Catalent’s major customers, the manufacturer has been hamstrung by its own balance sheet. With roughly $5 billion in debt on its books, it’s had to juggle paying down debt with sufficiently investing in its facilities. That’s been particularly challenging in keeping pace with soaring demand for GLP-1 drugs.

Novo, on the other hand, has the balance sheet to funnel as much money as needed into the plants in Italy, Belgium, and Indiana. It’s also struggled to make enough of its popular GLP-1 drugs to meet their soaring demand, with documented shortages of both Ozempic and Wegovy.

The impact won’t be immediate. The parties expect the deal to close near the end of 2024. Novo Nordisk said it expects the three new sites to “gradually increase Novo Nordisk’s filling capacity from 2026 and onwards.”

As for the rest of Catalent — nearly 50 other sites employing thousands of workers — Novo Holdings will take control. The group previously acquired Altasciences in 2021 and Ritedose in 2022, so the Catalent deal builds on a core investing interest in biopharma services, Novo Holdings CEO Kasim Kutay told Endpoints News.

Kasim Kutay

When asked about possible site closures or layoffs, Kutay said the team hasn’t thought about that.

“That’s not our track record. Our track record is to invest in quality businesses and help them grow,” he said. “There’s always stuff to do with any asset you own, but we haven’t bought this company to do some of the stuff you’re talking about.”

What does it mean for Catalent’s customers? 

Until the deal closes, Catalent will operate as a standalone business. After it closes, Novo Nordisk said it will honor its customer obligations at the three sites, a spokesperson said. But they didn’t answer a question about what happens when those contracts expire.

The wrinkle is the long-term future of the three plants that Novo Nordisk is paying for. Those sites don’t exclusively pump out Wegovy, but that could be the logical long-term aim for the Danish drugmaker.

The ideal scenario is that pricing and timelines remain the same for customers, said Nicole Paulk, CEO of the gene therapy startup Siren Biotechnology.

Nicole Paulk

“The name of the group that you’re going to send your check to is now going to be Novo Holdings instead of Catalent, but otherwise everything remains the same,” Paulk told Endpoints. “That’s the best-case scenario.”

In a worst case, Paulk said she feared the new owners could wind up closing sites or laying off Catalent groups. That could create some uncertainty for customers looking for a long-term manufacturing partner.

Are shareholders and regulators happy? 

The pandemic was a wild ride for Catalent’s stock, with shares surging from about $40 to $140 and then crashing back to earth. The $63.50 share price for the takeover is a happy ending depending on the investor.

On that point, the investing giant Elliott Investment Management is satisfied. Marc Steinberg, a partner at Elliott, called the agreement “an outstanding outcome” that “clearly maximizes value for Catalent stockholders” in a statement.

Elliott helped kick off a strategic review last August that culminated in the sale agreement. Compared to Catalent’s stock price before that review started, the deal pays a nearly 40% premium.

Alessandro Maselli

But this is hardly a victory lap for CEO Alessandro Maselli, who took over in July 2022 when Catalent’s stock price was north of $100. Novo’s takeover is a tacit acknowledgment that Maselli could never fully right the ship, as operational problems plagued the company throughout 2023 while it was limited by its debt.

Additional regulatory filings in the next few weeks could give insight into just how competitive the sale process was. William Blair analysts said they don’t expect a competing bidder “given the organic investments already being pursued at other leading CDMOs and the breadth and scale of Catalent’s operations.”

The Blair analysts also noted the companies likely “expect to spend some time educating relevant government agencies” about the deal, given the lengthy closing timeline. Given Novo Nordisk’s ascent — it’s now one of Europe’s most valuable companies — paired with the limited number of large contract manufacturers, antitrust regulators could be interested in taking a close look.

Are Catalent’s problems finally a thing of the past?

Catalent ran into a mix of financial and operational problems over the past year that played no small part in attracting the interest of an activist like Elliott.

Now with a deal in place, how quickly can Novo rectify those problems? Some of the challenges were driven by the demands of being a publicly traded company, like failing to meet investors’ revenue expectations or even filing earnings reports on time.

But Catalent also struggled with its business at times, with a range of manufacturing delays, inspection reports and occasionally writing down acquisitions that didn’t pan out. Novo’s deep pockets will go a long way to a turnaround, but only the future will tell if all these issues are fixed.

Kutay said his team is excited by the opportunity and was satisfied with the due diligence it did on the company.

“We believe we’re buying a strong company with a good management team and good prospects,” Kutay said. “If that wasn’t the case, I don’t think we’d be here.”

Amber Tong and Reynald Castañeda contributed reporting.

Read More

Continue Reading


Petrina Kamya, Ph.D., Head of AI Platforms at Insilico Medicine, presents at BIO CEO & Investor Conference

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb….



Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb. 26-27 at the New York Marriott Marquis in New York City. Dr. Kamya will speak as part of the panel “AI within Biopharma: Separating Value from Hype,” on Feb. 27, 1pm ET along with Michael Nally, CEO of Generate: Biomedicines and Liz Schwarzbach, PhD, CBO of BigHat Biosciences.

Credit: Insilico Medicine

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb. 26-27 at the New York Marriott Marquis in New York City. Dr. Kamya will speak as part of the panel “AI within Biopharma: Separating Value from Hype,” on Feb. 27, 1pm ET along with Michael Nally, CEO of Generate: Biomedicines and Liz Schwarzbach, PhD, CBO of BigHat Biosciences.

The session will look at how the latest artificial intelligence (AI) tools – including generative AI and large language models – are currently being used to advance the discovery and design of new drugs, and which technologies are still in development. 

The BIO CEO & Investor Conference brings together over 1,000 attendees and more than 700 companies across industry and institutional investment to discuss the future investment landscape of biotechnology. Sessions focus on topics such as therapeutic advancements, market outlook, and policy priorities.

Insilico Medicine is a leading, clinical stage AI-driven drug discovery company that has raised over $400m in investments since it was founded in 2014. Dr. Kamya leads the development of the Company’s end-to-end generative AI platform, Pharma.AI from Insilico’s AI R&D Center in Montreal. Using modern machine learning techniques in the context of chemistry and biology, the platform has driven the discovery and design of 30+ new therapies, with five in clinical stages – for cancer, fibrosis, inflammatory bowel disease (IBD), and COVID-19. The Company’s lead drug, for the chronic, rare lung condition idiopathic pulmonary fibrosis, is the first AI-designed drug for an AI-discovered target to reach Phase II clinical trials with patients. Nine of the top 20 pharmaceutical companies have used Insilico’s AI platform to advance their programs, and the Company has a number of major strategic licensing deals around its AI-designed therapeutic assets, including with Sanofi, Exelixis and Menarini. 


About Insilico Medicine

Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. 

Read More

Continue Reading